1-5 of 5
Timothy M. Kuzel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 5535: SEA-CD40 is a non-fucosylated anti-CD40 antibody with potent pharmacodynamic activity in preclinical models and patients with advanced solid tumors

Haley Neff-LaFord, Juneko E. Grilley-Olson, David C. Smith, Brendan Curti, Sanjay Goel, Timothy M. Kuzel, Svetomir N. Markovic, Olivier Rixe, David L. Bajor, Thomas F. Gajewski, Martin Gutierrez, Elisabeth I. Heath, John Thompson, Sahar Ansari, Shyra Gardai, Celine Jacquemont, Michael Schmitt, Andrew L. Coveler
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 5535.
https://doi.org/10.1158/1538-7445.AM2020-5535
Published: 15 August 2020
View article titled, Abstract 5535: SEA-CD40 is a non-fucosylated anti-CD40 antibody with potent pharmacodynamic activity in preclinical models and patients with advanced solid tumors
Journal Articles

Abstract 404: Prognostic value of soluble and cell surface immune-checkpoint molecules in advanced non-small cell lung cancer (NSCLC) patients receiving anti-PD-1/-L1 immunotherapy

Imad Tarhoni, Mary Jo Fidler, Ibtihaj Fughhi, Connor Wakefield, Revathi Kollipara, Maneet Multani, Marta Batus, Sanjib Basu, Wen-Rong Lie, Donna Russell, Jeffrey Martinson, Alan L. Landay, Timothy M. Kuzel, Philip Bonomi, Jeffrey A. Borgia
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 404.
https://doi.org/10.1158/1538-7445.AM2019-404
Published: 01 July 2019
View article titled, Abstract 404: Prognostic value of soluble and cell surface immune-checkpoint molecules in advanced non-small cell lung cancer (NSCLC) patients receiving anti-PD-1/-L1 immunotherapy
Journal Articles

Abstract 3827: NCI 8628 - A randomized phase II study of Ziv-aflibercept (Z) and high dose Interleukin-2 (IL-2) or IL-2 alone for inoperable stage III or IV melanoma

Ahmad A. Tarhini, Paul H. Frankel, Christopher Ruel, Marc S. Ernstoff, Timothy M. Kuzel, Theodore F. Logan, Nikhil I. Khushalani, Hussein A. Tawbi, Kim A. Margolin, Sanjay Awasthi, David F. McDermott, Alice Chen, Primo N. Lara, John M. Kirkwood
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 3827.
https://doi.org/10.1158/1538-7445.AM2017-3827
Published: 01 July 2017
View article titled, Abstract 3827: NCI 8628 - A randomized phase II study of Ziv-aflibercept (Z) and high dose Interleukin-2 (IL-2) or IL-2 alone for inoperable stage III or IV melanoma
Journal Articles

Host miR155 Promotes Tumor Growth through a Myeloid-Derived Suppressor Cell–Dependent Mechanism

Siqi Chen, Long Wang, Jie Fan, Cong Ye, Donye Dominguez, Yi Zhang, Tyler J. Curiel, Deyu Fang, Timothy M. Kuzel, Bin Zhang
Journal: Cancer Research
Cancer Res (2015) 75 (3): 519–531.
https://doi.org/10.1158/0008-5472.CAN-14-2331
Published: 01 February 2015
View article titled, Host miR155 Promotes Tumor Growth through a Myeloid-Derived Suppressor Cell–Dependent Mechanism
Open the PDF for Host miR155 Promotes Tumor Growth through a Myeloid-Derived Suppressor Cell–Dependent Mechanism in another window
Includes: Supplementary data
Journal Articles

Abstract LB-3: The recruitment of PP2A by TGF-β receptors mediates the response to TGF-β-induced activation of ERK in prostate cancer

Qiang Zhang, Lin Chen, Brian Helfand, James Kozlowski, Charles B Brendler, Timothy M. Kuzel, Chung Lee
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): LB-3.
https://doi.org/10.1158/1538-7445.AM2011-LB-3
Published: 15 April 2011
View article titled, Abstract LB-3: The recruitment of PP2A by TGF-β receptors mediates the response to TGF-β-induced activation of ERK in prostate cancer